Brown Advisory Inc. Sells 75,557 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Brown Advisory Inc. lessened its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 39.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 114,698 shares of the company's stock after selling 75,557 shares during the period. Brown Advisory Inc. owned approximately 0.07% of Xeris Biopharma worth $630,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp increased its position in Xeris Biopharma by 11.8% during the 1st quarter. Bank of New York Mellon Corp now owns 360,324 shares of the company's stock worth $1,978,000 after purchasing an additional 37,949 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Xeris Biopharma during the 1st quarter worth approximately $63,000. Wealth Enhancement Advisory Services LLC increased its position in Xeris Biopharma by 92.1% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 31,254 shares of the company's stock valued at $172,000 after acquiring an additional 14,986 shares during the period. Pallas Capital Advisors LLC acquired a new position in Xeris Biopharma in the 1st quarter valued at approximately $84,000. Finally, Apella Capital LLC acquired a new position in Xeris Biopharma in the 1st quarter valued at approximately $55,000. Institutional investors own 42.75% of the company's stock.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin Mcculloch acquired 25,000 shares of the company's stock in a transaction on Friday, June 13th. The shares were purchased at an average cost of $4.38 per share, with a total value of $109,500.00. Following the completion of the purchase, the insider owned 1,708,585 shares of the company's stock, valued at approximately $7,483,602.30. This represents a 1.48% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.47% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on XERS. Oppenheimer upped their price target on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Wall Street Zen cut shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Xeris Biopharma currently has an average rating of "Moderate Buy" and an average target price of $6.25.

Xeris Biopharma Stock Down 0.1%

NASDAQ:XERS traded down $0.01 during trading hours on Friday, reaching $5.23. The company had a trading volume of 781,841 shares, compared to its average volume of 2,064,669. The firm has a market cap of $817.09 million, a price-to-earnings ratio of -17.45 and a beta of 0.66. The business's 50-day simple moving average is $4.79 and its two-hundred day simple moving average is $4.35. Xeris Biopharma Holdings, Inc. has a twelve month low of $2.10 and a twelve month high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million. As a group, equities analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.